Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Assess the Safety and Tolerability of a Single Subretinal Administration of SPVN06 Gene Therapy in Subjects With Rod-Cone Dystrophy (RCD)

NCT05748873 is registered in ClinicalTrials.gov with SparingVision as lead sponsor.

NCT NCT05748873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05748873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Assess the Safety and Tolerability of a Single Subretinal Administration of SPVN06 Gene Therapy in Subjects With Rod-Cone Dystrophy (RCD)
Lead sponsor
SparingVision
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 12, 2023
Completion date
February 28, 2031
Enrollment
33 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

retinitis pigmentosa